Hep to hepatitis C

October 1997
CMAJ: Canadian Medical Association Journal;10/01/97, Vol. 157 Issue 7, p874
Academic Journal
No abstract available.


Related Articles

  • New Hope for Hepatitis C Patients.  // Primary Care Reports;Sep2013, Vol. 19 Issue 9, p18 

    The article focuses on the study regarding the efficacy of polymerase inhibitor sofosbuvir in treating hepatitis C (HEP-C).

  • New Hope for Hepatitis C Patients.  // Clinical Oncology Alert;Sep2013 Clincal Briefs, p18 

    The article offers information on polymerase inhibitor sofosbuvir which has showed high efficacy in both untreated and treatment failures of hepatitis C (HEP-C).

  • Be sure to test baby-boomers for hepatitis C.  // Clinical Advisor;Jul2012, Vol. 15 Issue 7, p21 

    The article announces the launch of the "I.D. Hep C" campaign by the American Gastroenterological Association (AGA) for educating and encouraging people to test for hepatitis C.

  • Ann Jesse tackles hepatitis C with a vengeance. Lusky, Mark; Lusky, Heather // ColoradoBiz;May2000, Vol. 27 Issue 5, p14 

    Features Ann Jesse and Hep C Connection, a hepatitis C network and support system in Denver, Colorado. How Jesse started her quest against hepatitis C; Patients with high risks of hepatitis C; Health consequence of untreated hepatitis C virus.

  • WaterFire Raises Awareness of Hep C.  // Rhode Island Medical Journal;Aug2014, Vol. 97 Issue 8, p48 

    The article reports on the WaterFire Lighting for RI Defeats Hep C event that was held on July 26, 2014 on World Hepatitis Day in Rhode Island to raise awareness towards hepatitis C infection.

  • Mylan launches generic sofosbuvir for treatment of hepatitis C.  // FRPT- Chemical Snapshot;5/10/2015, p14 

    The article announces the launch of the generic version of Hepatitis C drug sofosbuvir under the brand name MyHep by pharmaceutical company Mylan NV.

  • High cost burden of RA and hep C speciality drugs.  // PharmacoEconomics & Outcomes News;4/13/2013, Issue 676, p8 

    The article reports on two studies which found that the cost of rheumatoid arthritis (RA) and hepatitis C (hep C) speciality drugs now account for more than half of the total cost of care for patients with these conditions.

  • CVS Picks Gilead For H epatitis C Treatments. AMY REEVES // Investors Business Daily;1/6/2015, pA01 

    Monday brought a surprising turn to the twisting story of hepatitis C treatments, as pharmacy giant CVS Health said it will offer exclusive coverage for Gilead Sciences' hep C drugs.

  • How early is early enough?  // Gut;May2006, Vol. 55 Issue 5, p732 

    An abstract of the article "Early Monotherapy With Pegylated Interferon Alpha-2b for Acute Hepatitis C Infection: The HEP-NET Acute-II Study," by J. Wiegand, P. Buggisch and W. Boecher is presented.

  • Calendar of Courses, Symposiums, and Conferences.  // American Journal of Gastroenterology;Feb2012, Vol. 107 Issue 2, p330 

    A calendar of symposiums, conferences, and courses is presented which includes the Joint International Neurogastroenterology and Motility Meeting, the 2nd World Congress on Controversies in the Management of Viral Hepatitis (C-Hep), and Abdominal Radiology Course 2012.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics